Key facts
- This page summarizes Bruce Horowitz's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 22 Jun 2021, 17:23.
Bruce Horowitz - 17 Jun 2021 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
- Reporting relationship
- COO, Director
- Issuer ticker
- PVCT
- Reported as of
- 17 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Bruce Horowitz
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Bruce Horowitz filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 22 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PVCT
transaction
Derivative
8% Secured Convertible Promissory Notes due 2021
Award
- Transaction value
- $110,111
- Shares
- Change %
- Price
- Shares after
- $110,111
- Date
- 17 Jun 2021
- Ownership
- Direct
- Underlying class
- Series D-1 Convertible Preferred Stok
- Underlying amount
- 38,473
- Exercise price
- $2.86
- Footnotes
- F1
PVCT
transaction
Derivative
8% Secured Convertible Promissory Notes due 2021
Options Exercise
- Transaction value
- $110,111
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 20 Jun 2021
- Ownership
- Direct
- Underlying class
- Series D-1 Convertible Preferred Stock
- Underlying amount
- 38,473
- Exercise price
- $2.86
- Footnotes
- F2
PVCT
transaction
Derivative
Series D-1 Convertible Preferred Stock
Options Exercise
- Transaction value
- $0
- Shares
- +38,473
- Change %
- Price
- $0.000000
- Shares after
- 38,473
- Date
- 20 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 384,730
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Issuer issued the 8% secured convertible promissory notes due 2021 to the Reporting Person on March 18, 2020 (the "Notes"). At the time of issuance, the Issuer had not filed a Certificate of Designation for the Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Convertible Preferred Stock") and, therefore, there was no security underlying the Notes into which the Notes could convert. On June 17, 2021, the Issuer filed a Certificate of Designation with the Delaware Secretary of State to create the Series D-1 Convertible Preferred Stock and, upon the filing of the Certificate of Designation, the Notes became a derivative security.
Footnote F2
On June 20, 2021, the Notes automatically converted into Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the Notes.
Footnote F3
Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
Footnote F4
The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.